Abstract:Increased drug efficacy against tuberculosis (TB) can be achieved through re‐engineering old TB‐drug families and repurposing known drugs, leading to newer classes of compounds with novel mechanisms. This review discusses the structural aspects of developing new anti‐TB drugs, revealing that the fluoroquinolone, oxazolidinone, and nitroimidazole classes of compounds have great potential to be further explored for TB drug development. The prevalence of tuberculosis (TB) remains the leading cause of death from a single infectious agent, ranking it above all other contagious diseases. The problem to tackle this disease seems to become even worse due to the outbreak of SARS‐CoV‐2. Further, the complications related to drug‐resistant TB, prolonged treatment regimens, and synergy between TB and HIV are significant drawbacks. There are several drugs to treat TB, but there is still no rapid and accurate treatment available. Intensive research is, therefore, necessary to discover newer molecular analogs that can probably eliminate this disease within a short span. An increase in efficacy can be achieved through re‐engineering old TB‐drug families and repurposing known drugs. These two approaches have led to the production of newer classes of compounds with novel mechanisms to treat multidrug‐resistant strains. With respect to this context, we discuss structural aspects of developing new anti‐TB drugs as well as examine advances in TB drug discovery. It was found that the fluoroquinolone, oxazolidinone, and nitroimidazole classes of compounds have greater potential to be further explored for TB drug development. Most of the TB drug candidates in the clinical phase are modified versions of these classes of compounds. Therefore, here we anticipate that modification or repurposing of these classes of compounds has a higher probability to reach the clinical phase of drug development. The information provided will pave the way for researchers to design and identify newer molecular analogs for TB drug development and also broaden the scope of exploring future‐generation potent, yet safer anti‐TB drugs.

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery